SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)

被引：0
|
作者：
Chapman, Paul B. [1 ]
Sznol, Mario [2 ]
Lao, Christopher D. [3 ]
Gonzalez, Rene [4 ]
Daniels, Gregory A. [5 ]
Thompson, John A. [6 ]
Kudchadkar, Ragini R. [7 ]
Sharfman, William H. [8 ]
Atkins, Michael B. [9 ]
Pavlick, Anna C. [10 ]
Infante, Jeffrey R. [11 ]
Kim, Kevin B. [12 ]
Weber, Jeffrey S. [13 ]
Nair, Suresh [14 ]
Cowey, Lance [15 ]
Lipson, Evan J. [8 ]
Lee, Sue [16 ]
Avila, Alexandre [16 ]
Hodi, Stephen [17 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[2] Yale Canc Ctr, New Haven, CT USA
[3] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[4] Univ Colorado, Ctr Canc, Denver, CO 80262 USA
[5] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA
[6] Univ Washington, Seattle, WA 98195 USA
[7] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[8] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA
[9] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA
[10] NYU, New York, NY USA
[11] Tennessee Oncol PLLC, Sarah Cannon Res Inst, Nashville, TN USA
[12] Calif Pacific Ctr Melanoma Res, San Francisco, CA USA
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[14] Lehigh Valley Hosp, Allentown, PA USA
[15] Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA
[16] Bristol Myers Squibb, Princeton, NJ USA
[17] Dana Farber Canc Inst, Boston, MA 02115 USA
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 12卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
219
引用
收藏
页码：119 / 119
页数：1
相关论文
共 50 条
  • [21] EFFICACY AND SAFETY IN KEY PATIENT SUBGROUPS OF NIVOLUMAB (NIVO) ALONE OR COMBINED WITH IPILIMUMAB (IPI) VERSUS IPI ALONE IN TREATMENT-NAIVE PATIENTS WITH ADVANCED MELANOMA (MEL) (CHECKMATE 067)
    Larkin, James
    Chiarion-Sileni, Vanna
    Gonzalez, Rene
    Grob, Jean-Jacques
    Cowey, C. Lance
    Lao, Christopher D.
    Wagstaff, John
    Hogg, David
    Hill, Andrew
    Carlino, Matteo S.
    Wolter, Pascal
    Lebbe, Celeste
    Schachter, Jacob
    Thomas, Luc
    Hassal, Jessica C.
    Lorigan, Paul
    Walker, Dana
    Jiang, Joel
    Hodi, F. Stephen
    Wolchok, Jedd D.
    Asia-Pacific Journal of Clinical Oncology, 2015, 11 : 126 - 126
  • [22] Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. J.
    Cowey, C. L.
    Lao, C. D.
    Wagstaff, J.
    Hogg, D.
    Hill, A.
    Carlino, M. S.
    Wolter, P.
    Lebbe, C.
    Schachter, J.
    Thomas, L.
    Hassel, J. C.
    Lorigan, P.
    Walker, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J. D.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S664 - S665
  • [23] PD-L1 EXPRESSION AS A BIOMARKER FOR NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) AND NIVO ALONE IN ADVANCED MELANOMA (MEL): A POOLED ANALYSIS
    Long, Georgina
    Larkin, James
    Ascierto, Paolo
    Hodi, Stephen
    Rutkowski, Piotr
    Chiarion-Selini, Vanna
    Hassel, Jessica
    Lebbe, Celeste
    Pavlick, Anna
    Wagstaff, John
    Schadendorf, Dirk
    Dummer, Reinhard
    Hogg, David
    Haanen, John
    Corrie, Pippa
    Hoeller, Christopher
    Horak, Christine
    Wolchok, Jedd
    Robert, Caroline
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 126 - 126
  • [24] Efficacy and safety in key patient subgroups of nivolumab (NIVO) alone or combined with ipilimumab (IPI) versus IPI alone in treatment-naive patients with advanced melanoma (MEL) (CheckMate 067)
    Larkin, J.
    Chiarion-Sileni, V.
    Gonzalez, R.
    Grob, J. -J.
    Cowey, C. L.
    Lao, C. D.
    Wagstaff, J.
    Hogg, D.
    Hill, A.
    Carlino, M. S.
    Wolter, P.
    Lebbe, C.
    Schachter, J.
    Thomas, L.
    Hassel, J. C.
    Lorigan, P.
    Walker, D.
    Jiang, J.
    Hodi, F. S.
    Wolchok, J. D.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 40 - 40
  • [25] Efficacy and safety data from elderly patients with pretreated advanced melanoma in the Italian cohort of ipilimumab expanded access programme (EAP).
    Chiarion-Sileni, Vanna
    Pigozzo, Jacopo
    Ascierto, Paolo Antonio
    Maio, Michele
    Danielli, Riccardo
    Del Vecchio, Michele
    Ridolfi, Laura
    De Galitiis, Federica
    Testori, Alessandro
    Cocorocchio, Emilia
    Cognetti, Francesco
    Ferraresi, Virginia
    Bernengo, Maria Grazia
    Guida, Michele
    Antonuzzo, Andrea
    Mandala, Mario
    Parmiani, Giorgio
    Vanella, Vito
    Aglietta, Massimo
    Queirolo, Paola
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [26] THE EUROPEAN IPILIMUMAB EXPANDED ACCESS PROGRAMME (EAP): EFFICACY AND SAFETY DATA FROM THE ITALIAN COHORT OF PATIENTS WITH PRETREATED, ADVANCED MELANOMA
    Ascierto, P. A.
    Sileni, V. Chiarion
    Del Vecchio, M.
    Altomonte, M.
    De Galitiis, F.
    Ridolfi, L.
    Cognetti, F.
    Testori, A.
    Bernengo, M. G.
    Queirolo, P.
    ANNALS OF ONCOLOGY, 2012, 23 : 367 - 368
  • [27] ECONOMIC EVALUATION OF NIVOLUMAB (NIVO) PLUS IPILIMUMAB (IPI) COMBINATION AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED MELANOMA IN CANADA
    Quon, P.
    Xiao, Y.
    Sorensen, S.
    Schultz, M.
    Monfared, Tahami A. A.
    VALUE IN HEALTH, 2017, 20 (09) : A441 - A442
  • [28] Survival outcomes of nivolumab (NIVO) given sequentially with ipilimumab (IPI) in patients with advanced melanoma (CheckMate 064).
    Weber, Jeffrey S.
    Gibney, Geoffrey Thomas
    Sullivan, Ryan J.
    Sosman, Jeffrey Alan
    Slingluff, Craig L.
    Lawrence, Donald P.
    Logan, Theodore F.
    Schuchter, Lynn Mara
    Nair, Suresh
    Buchbinder, Elizabeth Iannotti
    Berghorn, Elmer
    Jiang, Joel
    Horak, Christine E.
    Hodi, F. Stephen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [29] Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (MBM; CheckMate 204)
    Tawbi, Hussein
    Forsyth, Peter
    Hodi, F. Stephen
    Lao, Christopher
    Moschos, Stergios
    Hamid, Omid
    Atkins, Michael B.
    Lewis, Karl
    Thomas, Reena P.
    Glaspy, John A.
    Jang, Sekwon
    Algazi, Alain
    Khushalani, Nikhil I.
    Postow, Michael A.
    Pavlick, Anna C.
    Ernstoff, Marc
    Reardon, David A.
    Balogh, Agnes
    Rizzo, Jasmine
    Margolin, Kim
    BRITISH JOURNAL OF CANCER, 2019, 121 : 20 - 20
  • [30] Phase 2 study to evaluate efficacy and safety of combination therapy with nivolumab (NIVO) and ipilimumab(IPI) in patients with previously untreated melanoma
    Kiyohara, Y.
    Takenouchi, T.
    Uhara, H.
    Koga, H.
    Uchi, H.
    Yamazaki, N.
    ANNALS OF ONCOLOGY, 2017, 28
12345